ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Mutations in the notch signalling pathway are associated with enhanced anti-tumour immunity in colorectal cancer

Wang, Fei; Long, Jie; Li, Liang; Zhao, Zhi-bin; Wei, Fang; Yao, Yuan; Qiu, Wen-Jing; Wu, Zi-Xin; Luo, Qing-Qing; Liu, Wei; Quan, Yi-Bo; Lian, Zhe-Xiong*; Cao, Jie*广州医学院; 1
Journal of Cellular and Molecular Medicine2020-10DOI: 10.1111/jcmm.15867
16被引4阅读
引用收藏
分享

摘要

The Notch signalling pathway is involved in the development of several cancers, including colorectal cancer (CRC). However, whether mutations in this pathway could alter the CRC immunophenotype remains unknown. Here, we investigated the relationship between Notch signalling pathway mutations and the tumour immune microenvironment by analysing gene expression data from the single T cell RNA sequencing data set and The Cancer Genome Atlas (TCGA) data set. We found that Notch signalling pathway mutations were associated with an increased number of tumour-specific CD8(+)T cells and decreased number of inhibitory regulatory T (Treg) cells, representing an enhanced anti-tumour response in the data set. In TCGA data set, we also found that Notch signalling pathway mutations were associated with enrichment of genes associated with immune activation pathways and higher expressions ofPDCD1,GZMBandPRF1. Although Notch signalling pathway mutations did not affect the overall survival and disease-free survival of CRC patients, they were associated with earlier disease stages and lower rates of metastasis. These results demonstrated that Notch signalling pathway mutations can enhance anti-tumour immunity in CRC, as validated by the two data sets, suggesting that they may be promising biomarkers for immune checkpoint blockade therapies for CRC patients.

学科与关键词

关键词
anti-tumour immunitycolorectal cancermutationnotch signalling pathwaytumour microenvironment
相关
加载中…
  • Notch signaling mutations increase intra-tumor chemokine expression and predict response to immunotherapy in colorectal cancer
    Wang, Fei; Huang, Chuan; Long, Jie; Zhao, Zhi-Bin; Ma, Hai-Qing*; Yao, Xue-Qing*; Li, Liang*; Lian, Zhe-XiongBMC CANCER, 2022, 22(1): 933.被引 8
  • Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer
    Lin, Anqi; Yao, Jiarong; Cheng, Quan; Liu, Zaoqu; Luo, Peng*; Zhang, Jian*Journal of Inflammation Research, 2023, 16: 1693-1709.被引 1
  • Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
    Lin, Anqi; Xu, Wentao; Luo, Peng*; Zhang, Jian*Frontiers in Pharmacology, 2021, 12: 721181.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Cellular and Molecular Medicine
发表日期
2020-10
卷期
第 24 卷, 第 20 期
页码
12176-12187
DOI
10.1111/jcmm.15867
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81871943]; Guangzhou Science Technology and Innovation Commission [201805010003]; Program for Guangdong Introducing Innovative and Entrepreneurial Teams [2017ZT07S054]

作者

  • W

    Wang, Fei (第一作者)

    1 · 2

  • L

    Long, Jie

    1 · 2 · univ sci & technol china

查看全部 13 位作者收起作者
  • L

    Li, Liang

    1 · 2

  • Z

    Zhao, Zhi-bin

    1 · 2

  • W

    Wei, Fang

    1 · 2

  • Y

    Yao, Yuan

    1 · 2

  • Q

    Qiu, Wen-Jing

    1 · 2

  • W

    Wu, Zi-Xin

    1 · 2

  • L

    Luo, Qing-Qing

    1 · 2

  • L

    Liu, Wei

    1 · guangzhou med univ

  • Q

    Quan, Yi-Bo

    1 · 2

  • L

    Lian, Zhe-Xiong (通讯)

    1 · 2

  • C

    Cao, Jie (通讯)

    1 · 2

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417